Barely Significant
← all excerpts

Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine.

Onco Targets Ther · 2010 · PMC2939768 · PMID 20856790

Europe PMCDOI
1
hedged sentence
0.1000
closest p · 2.0× alpha
0.1000
boldest claim

The sentences

did not reach statistical significanceP = 0.10so close (0.05 < p ≤ 0.1)
Although this finding did not reach statistical significance ( P = 0.10) possibly due to the effect of patient crossover, a subset survival analysis of patients receiving azacitidine compared with patients who either never crossed over or crossed over after 6 months of supportive care did reveal a statistically significant survival advantage highlighting the

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.